Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Blood (2022) 140 (Supplement 1): 10542–10544.

https://doi.org/10.1182/blood-2022-167098

Published: 2022

Journal Articles

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Matthew Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Christine Cornwell, Kamalika Banerjee, Anand Rotte, Christopher R. Heery, David Avigan, Andrzej Jakubowiak, Michael R. Bishop

Blood (2022) 140 (Supplement 1): 7439–7440.

https://doi.org/10.1182/blood-2022-163827

Published: 2022

Journal Articles

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Blood (2022) 140 (Supplement 1): 1328–1331.

https://doi.org/10.1182/blood-2022-157829

Published: 2022

Journal Articles

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Kirk Cahill, James Godfrey, Chadi Nabhan, Theodore G. Karrison, Jessica Robertson, Justin Kline, Kenneth S. Cohen, Michael R. Bishop, Walter M. Stadler, Reem Karmali, Parameswaran Venugopal, Seo-Hyun Kim, Aaron P. Rapoport, Sonali M. Smith

Blood (2022) 140 (Supplement 1): 6594–6595.

https://doi.org/10.1182/blood-2022-168444

Published: 2022

Journal Articles

Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

Blood (2022) 140 (Supplement 1): 2053–2055.

https://doi.org/10.1182/blood-2022-155950

Published: 2022

Journal Articles

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Shakthi Bhaskar, Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 10971–10973.

https://doi.org/10.1182/blood-2022-155886

Published: 2022

Journal Articles

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Blood (2022) 140 (Supplement 1): 10303–10306.

https://doi.org/10.1182/blood-2022-166432

Published: 2022

Journal Articles

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Blood (2022) 140 (Supplement 1): 1588–1591.

https://doi.org/10.1182/blood-2022-164674

Published: 2022

Journal Articles

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Vivek Patel, Shakthi Bhaskar, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Roni Shouval, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, David L. Porter, Michael R. Bishop, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 366–368.

https://doi.org/10.1182/blood-2022-165556

Published: 2022

Journal Articles

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Blood (2022) 140 (Supplement 1): 3158–3161.

https://doi.org/10.1182/blood-2022-158248

Published: 2022

Journal Articles

New hope to prevent ALL relapse after transplant

Michael R. Bishop

Blood (2022) 139 (17): 2580–2581.

https://doi.org/10.1182/blood.2022015611

Published: 2022

Journal Articles

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

Blood (2021) 138 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2021-155068

Published: 2021

Journal Articles

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, Jamie Brower, Loretta Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Joseph P. McGuirk, Veronika Bachanova, Wei-Ting Hwang, Stephen J. Schuster, Michael R. Bishop, David L. Porter

Blood (2021) 138 (Supplement 1): 2512.

https://doi.org/10.1182/blood-2021-151971

Published: 2021

Journal Articles

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Blood (2021) 138 (1): 11–22.

https://doi.org/10.1182/blood.2020009098

Published: 2021

Includes: Supplemental data

Journal Articles

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Jonathan A. Trujillo, James Godfrey, Yifei Hu, Jun Huang, Sonali M. Smith, Matthew J. Frigault, Zachariah DeFilipp, Daniel Appelbaum, Yonglin Pu, Nicholas Feinberg, Thomas Althaus, Michael R. Bishop, Peter A. Riedell, Justin Kline

Blood (2021) 137 (24): 3454–3459.

https://doi.org/10.1182/blood.2020009148

Published: 2021

Journal Articles

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Hongtao Liu, MD PhD, Bulent Aydogan, MD, Yasmin Hasan, MD, Amy Wang, MD MPH, Kamil Yenice, MD, Julien Partouche, MD, Wendy Stock, MD, Richard A. Larson, MD, Satyajit Kosuri, MD, James LaBelle, MD PhD, Justin Kline, MD, Peter A. Riedell, MD, Andrew S. Artz, MD, Michael R. Bishop, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138554

Published: 2020

Journal Articles

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

Ulrich Jaeger, MD, Michael R. Bishop, MD, Gilles Salles, MDPhD, Stephen J. Schuster, MD, Richard T. Maziarz, MD, Xia Han, MS, Alexander Savchenko, MD, Nathan Roscoe, Mbt, Elena Orlando, PhD, Dawson Knoblock, PhD, Ranjan Tiwari, MSc, Lida Bubuteishvili Pacaud, MD, Paolo Corradini

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137045

Published: 2020

Journal Articles

Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma

Matthew J Frigault, MD MSc, Michael R. Bishop, MD, Elizabeth K. O'Donnell, MD, Noopur S. Raje, MD, Allegra Mondillo, Daniella Cook, Heather Daley, Carissa Mangus, David W LeFleur, Janine M Buonato, Justin P Edwards, Laura K Richman, DVM, PhD, Maria T Polianova, PhD, Maria Sabatino, MD, Scott Currence, Angela Shen, MD, Travis Quigley, MS, Marcela V. Maus, MD PhD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-142931

Published: 2020

Journal Articles

The benefit of CAR T cells in older patients

Michael R. Bishop

Blood (2020) 135 (23): 2020–2021.

https://doi.org/10.1182/blood.2020005592

Published: 2020

Journal Articles

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, MD, Chase Walling, BS, Loretta J. Nastoupil, MD MSc, Martina Pennisi, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Olalekan O. Oluwole, MBBS, MPH, Veronika Bachanova, MD PhD, Wei-Ting Hwang, PhD, Stephen J. Schuster, MD, Miguel-Angel Perales, MD, Michael R. Bishop, MD, David L. Porter, MD

Blood (2019) 134 (Supplement_1): 1599.

https://doi.org/10.1182/blood-2019-127490

Published: 2019

NARROW

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

New hope to prevent ALL relapse after transplant

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study

A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma

The benefit of CAR T cells in older patients

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only